"Dr. Medve has a proven track record of leadership in pain drug development, including advancing multiple therapeutics through all phases of development, from preclinical data and IND filing to regulatory approval and commercial launch," said
Dr. Medve brings to Cara more than 20 years of experience in drug development and pain management, most recently serving as Senior Vice President and Chief Medical Officer at Nektar Therapeutics, where he led clinical development strategy and execution across a broad pipeline in multiple therapeutic areas, including pain. Previously, Dr. Medve was Chief Medical and Regulatory Officer at
Dr. Medve, an anesthesiologist and pain management specialist, completed his residency in anesthesia at
"I am very pleased to join Cara at this critical time in pain management. The need for new approaches to treating patients in pain, without mu-opioid side effects, including the potential for abuse, has never been greater," said Dr. Medve. "The high degree of pharmacological selectivity for peripheral kappa opioid receptors and the lack of mu receptor activity underlie the significant potential for CR845 to change our approach to managing pain, and reduce the need for mu-opioids and the risks they present."
CR845 is a peripherally acting kappa opioid receptor agonist currently in development for the treatment of acute and chronic pain. In multiple randomized, double-blind, placebo-controlled Phase 2 trials in patients undergoing laparoscopic hysterectomy or bunionectomy procedures, I.V. CR845 treatment resulted in statistically significant reductions in pain intensity and opioid-related side effects. In over 400 subjects dosed to date, I.V. CR845 was found to be safe and well tolerated, without incurring the dysphoric and psychotomimetic side effects that have been reported with centrally acting (CNS-active) kappa opioid receptor agonists.
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Examples of these forward-looking statements include statements concerning the future development of the Company's product candidates. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Risks are described more fully in
CONTACT: CORPORATE CONTACT:Source:
Derek ChalmersPresident & CEO Cara Therapeutics, Inc.203-567-1500 MEDIA CONTACT: Laura Bagby6 Degrees 872-206-5475 lbagby@6degreesPR.com INVESTOR CONTACT: Jesse BaumgartnerStern Investor Relations 212-362-1200 Jesse@sternir.com
News Provided by Acquire Media